• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hirudin alleviates acute ischemic stroke by inhibiting NLRP3 inflammasome-mediated neuroinflammation: In vivo and in vitro approaches
In this study, hirudin with a dose of 10-40 mg/kg was given to middle cerebral artery occlusion/reperfusion mice. Hirudin markedly constrained cerebral infarct area in a dose-dependent manner, and significantly improved locomotor disability at 40 mg/kg dose. Similar to MCC950, a selective NLRP3 inflammasome inhibitor, hirudin inhibited M1 polarization and promoted M2 polarization. It also strikingly suppressed the ischemia-induced overexpression of NLRP3 and its downstream components, caspase-1, apoptosis-associated speck-like protein (ASC), and interleukin-1β (IL-1β). Hirudin and MCC950 equivalently protected viability ...
Source: International Immunopharmacology - June 20, 2022 Category: Allergy & Immunology Authors: Wen-Qi Li Zong-Shi Qin Shuang Chen Dan Cheng Si-Chang Yang Yuen Man Mandy Choi Buggic Chu Wei-Hai Zhou Zhang-Jin Zhang Source Type: research

Inhibition of hypoxia inducible factor 1 by YC-1 attenuates tissue plasminogen activator induced hemorrhagic transformation by suppressing HMGB1/TLR4/NF- κB mediated neutrophil infiltration in thromboembolic stroke rats
Int Immunopharmacol. 2021 Feb 28;94:107507. doi: 10.1016/j.intimp.2021.107507. Online ahead of print.ABSTRACTHemorrhagic transformation (HT) is a frequent complication of ischemic stroke after thrombolytic therapy and seriously affects the prognosis of stroke. Due to the limited therapeutic window and hemorrhagic complications, tissue plasminogen activator (t-PA) is underutilized in acute ischemic stroke. Currently, there are no clinically effective drugs to decrease the incidence of t-PA-induced HT. Hypoxia-inducible factor 1 (HIF-1) is an important transcription factor that maintains oxygen homeostasis and mediates neuro...
Source: International Immunopharmacology - March 3, 2021 Category: Allergy & Immunology Authors: Linglei Kong Yinzhong Ma Zhiyuan Wang Nannan Liu Guodong Ma Chengdi Liu Ruili Shi Guanhua Du Source Type: research